Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade

11 Jul 2018

• By Joseph Haas

Two businessmen pulling a rope, closeup shot tug of war

Related Content

Indivior To Appeal US Suboxone Setback, Flags Follow-On Drug RBP-6000

02 Sep 2017

Sublocade Approval Grows Indivior's Opioid Addiction Franchise In Competitive Market

02 Dec 2017

Abuse-Deterrent Opioids: Where Are They Now?

20 Mar 2018

Dr. Reddy's Launches First Generic Suboxone Film; Indivior May Seek Injunction

17 Jun 2018

Braeburn Gets CRL For CAM2038 In Opioid Use Disorder, Yields Ground To Indivior

23 Jan 2018

KemPharm And The Curious Case Of Launching A Brand Opioid Like A Generic

26 Feb 2018

What's Driving Price Increases For Addiction Treatment Drugs?

27 Sep 2016

Related Companies

Indivior plc

Dr. Reddy's Laboratories Ltd.

Viatris Inc.

Par Pharmaceutical Companies Inc.

Zevra Therapeutics, Inc.

Alkermes plc

Apple Tree Partners

Additional Topics

Business Strategies Commercial Generic Drugs Intellectual Property BioPharmaceutical Neurology

More from Business

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.